|
| | NEW CORE TOOLS FOR OUR COMMUNITY |
|
| | In November, we launched a new partnership with Tecan and are pleased to announce several new instruments now available in our core facilities across our five MBC BioLabs sites. These systems expand our capabilities in plate reading, multiomics, automation, and single-cell workflows — and we’re excited to see our resident scientists put these great instruments to work.
Contact us if you’d like to tour our labs or discuss how to get started at MBC BioLabs and take advantage of our shared equipment. |
|
| Infinite Pro 200 (Infinite M Plex)Location: 1030 Brittan Ave, San Carlos
A fully loaded multimode plate reader with monochromator-based optics, supporting a wide range of assay formats and detection modes for flexible, high-performance, plate-based assays.
|
|
|
| Duo Digital Dispenser™Location: 1030 Brittan Ave, San Carlos
Combines single-cell isolation and reagent dispensing in a single benchtop instrument to streamline workflows and enable faster, more reproducible, high-precision experiments.
|
|
|
|
|
|
|
|
|
|
|
|
| Fluent Dreamprep NGSLocation: 1030 Brittan Ave, San Carlos
An advanced automation platform delivering exceptional positional accuracy and pipetting precision, offering security and peace of mind for walkaway processing. Its 52 deck grids accommodate up to 48 microplates (ANSI/SBS/SLAS format) to support high-throughput, reproducible NGS and liquid-handling workflows.
|
|
|
| Spark DuoLocation: 930 Brittan Ave, San Carlos
An all-in-one plate reader for fast spectral scanning, ELISAs, and low-volume DNA/protein quantification, featuring fast absorbance measurements, a cuvette port, and the patented NanoQuant Plate™.
|
|
|
|
|
|
|
|
|
|
|
|
| Veya Multiomics PlatformLocation: 135 Mississippi St, San Francisco
A multiomics platform that automates both research and clinical workflows using pre-developed scripts for quick setup and reliable results, enabling a wide variety of multiomic applications with minimal user interaction.
|
|
|
| Spark® CytoLocation: 733 Industrial Rd, San Carlos
A plate reader for 2D and 3D cell experiments with live cell imaging and real-time cytometry. The Spark Cyto combines high-performance camera components with proprietary imaging technology to capture the entire well area of 96- or 384-well plates in a single image, without tiling or distortion.
|
|
|
|
|
|
|
|
|
|
|
|
| | | | | Siolta Therapeutics reports positive phase 2 results from the ADORED (Allergic Disease Onset pREvention) Study
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | General Proximity announces multi-target collaboration with Daiichi Sankyo to advance novel oncology therapeutics
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Junevity expands seed funding to $20M to advance siRNA reprogramming
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Tahoe Therapeutics releases open-source virtual cell model to accelerate discovery
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | DeepSeq.AI joins Illumina Ventures Labs as its newest company
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Aperture Therapeutics announces CD33-targeting candidate for FTD and ALS
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | General Control joins Novo Nordisk’s Co-Creation Greenhouse Program to develop epigenetic activation platform
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Integrated Biosciences introduces scientific advisory board of leaders in synthetic biology and aging research
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | | | Lunch & Learn with Refeyn: mRNA Characterization with Mass Photometry
December 4th @ 12-1pm
135 Mississippi St, San Francisco
Join us for a seminar on how mass photometry can elevate mRNA and gene delivery research. Learn how rapid, label-free measurements reveal mRNA purity, encapsulation efficiency, and complex formation in LNP and viral vector workflows.
REGISTER ► |
|
| Chemometec Presentation and Demo: XcytoMatic® 40
November 5th @ 12-1pm
135 Mississippi St, San Francisco
Our partners at Chemometec will be onsite for a presentation and live demo of the XcytoMatic® 40, a high-throughput carousel cell counter that combines brightfield and fluorescent imaging for unparalleled accuracy and speed — no trypan blue required! Process up to 100 samples per hour with intuitive workflow automation that enhances efficiency and reproducibility in cell culture, QC, and drug discovery applications. Lunch will be provided.
REGISTER ► |
|
| MBC BioLabs Life Science Vendor Showcase
December 9th @ 11am-2pm
135 Mississippi St, San Francisco
We look forward to seeing you at the final Life Science Vendor Showcase of the year, bringing together innovative scientific and business solutions tailored for early-stage biotech teams. Meet industry experts, explore new technologies, and discover tools that can accelerate your work at MBC BioLabs.
REGISTER ► |
|
| Holiday Toy Drive for Family House
Deadline: December 12th
Drop-off at any MBC BioLabs location
We’ve partnered with Biocom California, Triple Ring, and Life Science Cares Bay Area to support the annual Holiday Toy Drive for Family House — and we’d love for our community to join us.
Drop off a new, unopened toy at any MBC BioLabs lobby from 8:30 AM-5 PM through December 12, or donate via the Amazon wish list. Every gift helps bring comfort and joy to families with children receiving care at UCSF Benioff Children’s Hospital.
LEARN MORE & DONATE HERE ► |
|
|
|
|
|
|
|
|
|
|
|
| | MEET OUR NEWEST RESIDENTS |
|
| | | Medra combines the intelligence of general-purpose robots with the scientific reasoning of large language models to run lab experiments. Our robots can automate full end-to-end scientific protocols and are used to accelerate scientific discovery. We've built AI specifically for the lab, designed to generate more data and ultimately lead to more breakthroughs.
Welcome to the 953 Indiana community in San Francisco, Cali Nguyen (Scientist) and Gaurav Agrawal (Engagement Manager)! We are delighted to have you!
LEARN MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Ligo Biosciences is building generative deep learning models for de novo protein design. Ligo was founded by a team of Oxford research scientists Edward Harris (CEO), Arda Goreci (CTO), Emily Egerton-Warburton (CSO) and Oliver Cort (Founding Engineer) in 2024 and moved to the Bay Area for YCS24. They gained recognition for their open-source implementation of AlphaFold3 and have since been building new protein design models to create enzymes with new-to-nature functionalities.
We’re thrilled to welcome Ligo Bio to the 135 Mississippi community in San Francisco. Their team is eager to meet Bay Area scientists, especially those working with enzymes. Please say hello if you spot them in the labs!
LEARN MORE ► |
|
| | Exonic is transforming drug discovery into an open, global project. We are using AI to build game-like interfaces that enable anyone, from PhDs to high schoolers, to design real DNA, RNA, and protein sequences. These inventions are tested in the lab, with promising discoveries advancing toward new therapies. Exonic's mission is to build the largest preclinical drug discovery pipeline in the world, powered by the world.
We’re pleased to welcome Ben Brimacombe (CEO) and Mikhail “Misha” Kulak (CSO) to our community at 953 Indiana in San Francisco. Please say hello if you see them around the labs.
LEARN MORE ►
|
|
| | CoFlo Medical enables the delivery of high-dose drugs by eliminating the viscosity barrier that often challenges formulation development. CoFlo devices use a special fluidic phenomenon to lubricate the flow of the drug without requiring any formulation changes, making drugs easily injectable no matter how high their viscosity. This enables pharma partners to develop more powerful formulations, minimize the burden of dose escalation trials, and bring products to market that improve the patient experience through faster and less frequent administration.
A warm welcome to CoFlo as they join our 135 Mississippi community in San Francisco. Their CEO, Simon Rufer, is often in the lab and community spaces — and you’ll likely see him at the MBC Run Club on Thursdays.
LEARN MORE ►
|
|
| | Resero Bio is building the next frontier in liquid biopsies that profile the cancer transcriptome non-invasively. Our NGS technology captures cancer-derived cell-free RNA with unmatched sensitivity and specificity, delivering a real-time view of tumor biology beyond the limits of tissue biopsy and enabling cancer detection as well as non-invasive cancer subtyping, risk stratification, therapeutic response prediction, and resistance profiling.
We are thrilled to welcome the team joining our 1030 Brittan community: Monica Nesselbush (CEO & Co-founder), Max Diehn (Co-founder & Scientific Advisor), Ash Alizadeh (Co-founder & Scientific Advisor), and Emily Hamilton (Founding Scientist, Assay Development).
LEARN MORE ►
|
|
| | NovaCode Bio is developing two advanced platforms for precision therapeutic delivery. The first is a nanobody-based platform designed to leverage the high affinity and molecular precision of nanobodies. The second is a peptide-based platform that employs non-canonical amino acids to enable the design of novel multi-cyclic peptides and related modalities. These platforms are integrated with biocompatible nano-delivery systems engineered for targeted payload release within tumor microenvironments. Together, these technologies aim to enhance therapeutic localization, improve efficacy, and advance the treatment potential of oncology interventions.
We’re excited to welcome COO Steve Mason to the 1030 Brittan community in San Carlos!
LEARN MORE ►
|
|
| | AcroCyte Therapeutics is closing the gap between laboratory models and patient-specific medicine. Our core technology, the R³CE® platform, is an easy-to-use, FDA-designated Class I, scaffold-free system that rapidly expands minimal patient specimens—like circulating tumor cells, needle biopsies and frozen tissues—into functional 3D organoids in days. This breakthrough powers our commercial Onco-REAL™ clinical service, which provides comprehensive functional analysis from liquid biopsies for timely oncology decisions, while our autologous cell therapy pipeline aims to transform a patient’s own cells into curative solutions. We empower academic, clinical, and industry partners worldwide to leverage the R³CE® platform for novel drug discovery, diagnostics, and regenerative medicine, providing a foundational technology limited only by imagination.
Welcome to the 1030 Brittan community, CEOs Ying Chang and Yao-Ting Wang, and Senior Scientists Yung-Hao Lin and Kai-Yu Huang. We are delighted to have you!
LEARN MORE ►
|
|
| | | | | |
|
|
|
| |
|
